Sunitinib-induced acute hemolysis without hypertension: a case report.
Sunitinib-associated hematologic adverse events are well known and include leukopenia, neutropenia, thrombocytopenia, anemia, and lymphopenia. Herein, we report the case of a patient with metastatic renal cell carcinoma who was treated with sunitinib and developed severe hemolysis without hypertension or reversible posterior leukoencephalopathy. Prompt discontinuation of the agent resulted in resolution of this complication.
Jain
Rajul
R
Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Mathew
Paul
P
Wood
Christopher G
CG
Tannir
Nizar M
NM
D000970:Antineoplastic Agents / Q000009:adverse effects; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D006461:Hemolysis / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007211:Indoles / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000009:adverse effects*; D000077210:Sunitinib
D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib